Under this collaboration, IBA will equip the proton therapy system and the proton gantry treatment room at the Fred Hutchinson Cancer Center with ConformalFLASH research functionality, which will enable preclinical research on FLASH therapy.

August 5, 2022 —  IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, Fred Hutchinson Cancer Center and the University of Washington (UW), Seattle, announced a multi-year research collaboration on ConformalFLASH[1] Proton Therapy. Under this collaboration, IBA will equip the proton therapy system and the proton gantry treatment room at the Fred Hutchinson Cancer Center with ConformalFLASH research functionality, which will enable preclinical research on FLASH therapy. In the future this could lead to a new clinical functionality for patients.
Radiation therapy has advanced drastically in the last few decades because of continued technological innovation, allowing for safer and more accurate methods to treat a comprehensive range of solid tumors. FLASH radiation, defined as the delivery of radiation at ultra-high dose rates (40-60Gy/s), has been shown to spare to normal tissue toxicity while maintaining an equivalent anti-tumor efficacy[2],[3]. FLASH is expected to dramatically change the landscape of radiotherapy and patient cancer care by enhancing the therapeutic window with less toxicity, allowing shorter treatment times and potential for dose escalation on radioresistant tumors for improved tumor control. IBA's ConformalFLASH approach combines the biological sparing effects of FLASH with the use of the spatial selectivity of the Proton Bragg peak.
As part of this collaboration, UW School of Medicine scientists will lead a comprehensive bench-to-bedside program at the Fred Hutchinson Cancer Center to analyze FLASH‐Radiotherapy (FLASH-RT) in pre‐clinical models to optimally deployed FLASH-RT for cancer patients. The focus would be to evaluate the optimal physical parameters for proton FLASH irradiation, including Pencil Beam Scanning (PBS) FLASH dose rates and FLASH effects in the Spread-Out Bragg Peak (SOBP). Swati Girdhani, Director, Research Collaborations at IBA, said: "In the last few years, IBA has been working closely with customers to support innovation, leading to breakthrough technologies like ConformalFLASH. In this era of value-centered medicine, ConformalFLASH has the potential to advance radiotherapy towards increased use of ultra-hypofractionation while significantly improving the therapeutic index. We are delighted to be working with the University of Washington, one of the leading centers for research in the United States to bring ConformalFLASH technology to patients." For more information: www.iba-worldwide.com 

References: 

[1] ConformalFLASH is a registered brand of IBA’s Proton FLASH irradiation solution currently under research and development phase.
[2] Diffenderfer et al IJROBP 2020 "Design, Implementation, and in Vivo Validation of a Novel Proton FLASH Radiation Therapy System".
[3] Velalopoulou et al Cancer Research 2021 "FLASH Proton Radiotherapy Spares Normal Epithelial and Mesenchymal Tissues While Preserving Sarcoma Response". 


Related Content

News | Radiology Education

April 21, 2025 — On June 20, the American Society of Radiologic Technologists (ASRT) will award Life Member status to ...

Time April 21, 2025
arrow
News | Radiology Business

April 16, 2025 — According to a new report, the U.S. Radiotherapy Market is projected to reach $2.49 billion by 2030 ...

Time April 17, 2025
arrow
News | ASTRO

March 14, 2025 — Another pivotal milestone in the nation’s fight against cancer recently took place with the ...

Time March 17, 2025
arrow
News | Computed Tomography (CT)

Royal Philips recently received 510(k) clearance from the US Food and Drug Administration (FDA) for its detector-based ...

Time November 13, 2024
arrow
News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | Radiology Business

July 31, 2024 — The American Registry of Radiologic Technologists (ARRT) announced the three Registered Technologists (R ...

Time July 31, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | Radiation Therapy

July 22, 2024 — RefleXion Medical, an external-beam theranostic oncology company, today announced that researchers from ...

Time July 22, 2024
arrow
Subscribe Now